期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

结肠癌中DcR3和livin表达与预后的关系 被引量：5

暂未订购
导出
摘要 目的探讨DcR3和livin在结肠癌组织中的表达与预后的关系。方法采用二步法免疫组化技术(Envision),检测62例术前未经化疗的结肠癌组织中DcR3和livin基因的表达情况。结果 62例结肠癌组织中DcR3阳性表达率56.5%(35/62);而livin阳性率48.4%(30/62)。DcR3和livin表达与结肠癌组织学类型、浸润深度、临床分期和淋巴结转移有明显相关性(P<0.05);与患者年龄、性别、肿瘤大小等无关(P>0.05)。DcR3在livin阳性和阴性患者中阳性率分别为68.6%(24/35)和22.2%(6/27),两者差异有统计学意义(P<0.05)。结肠癌DcR3和livin均阴性表达病例的5年生存率高于DcR3和livin均阳性表达者,两者差异有统计学意义(P<0.05)。结论 DcR3和livin异常表达可促进结肠癌的发生发展,同时两者具有协同作用,其与肿瘤的恶性程度与生存率有关;联合检测DcR3和livin更有助于判断结肠癌的发展趋势,为临床诊治及判断预后提供新的路径。
作者 刘祖宏 倪仰鹏 黄绮国 谢丽霞 许文兵 钟雪云
机构地区 广东省揭阳市人民医院病理科 暨南大学医学院病理教研室
出处 《广东医学》 CAS CSCD 北大核心 2013年第7期1055-1057,共3页 Guangdong Medical Journal
基金 国家自然科学基金面上项目(编号:81072059) 广东省医学科研基金资助项目(编号:A2007746)
关键词 肿瘤 结肠癌 DCR3 LIVIN 免疫组织化学 生存期
分类号 R697 [医药卫生—泌尿科学]
  • 相关文献

参考文献8

  • 1ASHKENAZI A. Targeting death and decoy receptors of the tumour - necrosis factor superfamily [ J ]. Nat Rev Cancer, 2002, 2 ( 6 ) : 420 - 430.
  • 2CHANG Y C, CHAN Y H, JACKSON D G, et al. The glycosami- noglycan -binding domain of decoy receptor 3 is essential for in- duction of monocyte adhesion [ J ]. J Immunol, 2006, 176 ( 1 ) : 173 - 180.
  • 3KASOF G M, GOMES B C. Livin, a novel inhibitor of apop tosisp rotein family member[J]. J Biol Chem, 2001, 276(5): 3238 - 3246.
  • 4SALVESEN G S, DUCKETY C S. IAP proteins : blocking the road to death's door[J]. Nat Rev Mol Cell Biol, 2002, 3(6) : 401 -410.
  • 5HARIU H, HIROHASHI Y, TOR1GOE T, et al. Aberrant expres- sion and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML - IAP in lung cancer[ J ]. Clin Cancer Res, 2005, 11(3): 1000-1009.
  • 6YAGIHASH I A, ASANUMA K, TSUJI N, et al. Detection of anti - livin antibody in gastrointestinal cancer patients [ J]. Clin Chem, 2003, 49(7) : 1206 - 1208.
  • 7陆娜娜,尹玉,曹立宇,李昊,江燕.大肠癌中Livin和Survivin的表达及相关性研究[J].中国组织化学与细胞化学杂志,2012,21(3):250-254. 被引量：7
  • 8GILL R M, HUNTR J S. Soluble receptor(DcR3) and cellular in- hibitor of apoptosis - 2 (cIAP - 2 ) protect human cytotrophoblast cells against LIGHT - mediated apoptosis [ J ]. Am J Pathol, 2004, 165(1) : 309 -317.

二级参考文献17

  • 1黎军和,何文静,何友兼.Survivin和Livin在Dukes'B期结直肠癌中的表达及其临床意义[J].癌症,2007,26(5):547-551. 被引量：37
  • 2Altieri DC. Survivin,versatile modulation of cell division and apoptosis in cancer[J].Oncogene,2003,(53):8581-8589.doi:10.1038/sj.onc.1207113.
  • 3Lin JH,Deng G,Huang Q. KIAP,a novel member of the inhibitor of apoptosis protein family[J].Biochemical and Biophysical Research Communications,2000,(03):820-831.doi:10.1006/bbrc.2000.4027.
  • 4Kappler M,Rot S,Taubert H. The effects of knockdown of wild-type Survivin,Survivin-2B or Survivin-Delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions[J].Cancer Gene Therapy,2007,(12):994-1001.doi:10.1038/sj.cgt.7701090.
  • 5Kasof GM,Gomes BC. Livin,a novel inhibitor of apoptosis protein family menber[J].Journal of Biological Chemistry,2001,(05):3238-3246.doi:10.2967/jnumed.108.059576.
  • 6Ashhab Y,Alian A,Polliack A. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern[J].FEBS Letters,2002,(12):56-60.
  • 7Vucic D,Stennicke HR,Pisabarro MT. MLIAP,a novel inhibitor of apoptosis that is preferentially expressed in human melanomas[J].Current Biology,2000,(21):1359-1366.
  • 8Ambrosini G,Adida C,Altieri DC. A novel anti-apoptosis gene,survivin,expressed in cancer and lymphoma[J].Nature Medicine,1997,(08):917-922.doi:10.1038/nm0897-917.
  • 9Ling X,Yang J,Tan D. Diferential expression of Survivin-2B and Survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-smallcell lung cancer(NSCLC)[J].Lung Cancer,2005,(03):353-361.doi:10.1016/j.lungcan.2005.03.037.
  • 10Takashima H,Nakajima T,Moriguchi M. In Vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma[J].Liver International,2005,(01):77-84.doi:10.1111/j.1478-3231.2004.0979.x.

共引文献6

同被引文献60

  • 1王晓玲,沈志祥,沈磊,于皆平,罗和生,滕小军,郭洁.瘦素对5-氟尿嘧啶损伤结肠癌细胞的影响[J].中国药理学通报,2006,22(4):492-496. 被引量：9
  • 2孙军,沈磊,罗和生,沈志祥.结肠癌瘦素和瘦素受体表达及其意义[J].中华消化杂志,2006,26(8):561-562. 被引量：11
  • 3王仕军.2型糖尿病患者血中瘦素、神经肽Y和肿瘤坏死因子α的变化探析[J].中因医药指南,2013,11(1):568-569.
  • 4高国仿,沈磊,罗和生,谭诗云,孙军,沈志祥.瘦素对结肠癌细胞株HT-29的影响[J].武汉大学学报（医学版）,2008,29(1):31-33. 被引量：3
  • 5LIM M, HUSSAIN Z, HOWE A, et al. The oncological outcome after right hemicolectomy and accuracy of CT scan as a preoperative tool for staging in right sided colonic cancers[ J]. Colorectal Dis, 2013,15(5) : 536 -543.
  • 6BUCCHERI S, GUGGINO G, CACCAMO N, et al. Efficacy and safety of γδT cell - based tumor immunotherapy : a meta- analysis [J]. J Biol Regul Homeost Agents, 2014, 28(1) : 81 -90.
  • 7SCHEPER W, SEBESTYEN Z, KUBALL J. Cancer immunothera- py using γδT cells : dealing with diversity [ J ]. Front Immunol, 2014, 5: 601.
  • 8KOBAYASHI H, TANAKA Y. γδT cell immunotherapy a re- viewIJ]. Pharmaceuticals ( Basel), 2015, 8( 1 ) : 40 -61.
  • 9KALE A, GAWANDE S, KOTWAL S. Cancer phytotherapeutics: role for flavonoids at the cellular level[ J ]. Phytother Res, 2008, 22 (5) : 567 - 577.
  • 10NOORI S, HASSAN Z M, YAGHMAEI B, et al. Antitumor and immunomodulatory effects of salvigenin on tumor bem-ing mice [ J ]. Cell Immunol, 2013, 286(1/2) : 16 -21.

引证文献5

二级引证文献14

广东医学
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部